Cycloprolylglycine (CPG)


Endogenous dipeptide / noopept metabolite

An endogenous dipeptide present in mammalian CSF; the principal active metabolite of noopept and a research probe for endogenous nootropic mechanisms.

Abstract

Cycloprolylglycine (CPG; cyclic Pro-Gly dipeptide) is an endogenous cyclic dipeptide identified in human cerebrospinal fluid and brain tissue. The compound is the principal active metabolite of noopept (formed by enzymatic cyclization after the parent compound’s hydrolysis) and has been investigated as an independent research probe. Pharmacology overlaps with noopept: BDNF and NGF upregulation, antioxidant effects, modulation of NMDA and AMPA receptor expression, modest cholinergic facilitation. CPG itself is sold as a research peptide for investigators studying the noopept mechanism without the parent compound’s prodrug pharmacology. Pharmacokinetics: plasma half-life ~2 hours; oral bioavailability presumed adequate. Doses are not formally established; rodent doses scale to micrograms per kilogram.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph